@LWebb
and of course the great thing about the individual drugs used in IHLs proprietary 42X is that they both carry individual
FDA approval for treatment indications in they're own right:Acetazolamide approved for the treatment of glaucoma / interocular pressure
Dronabinol approved in the treatment of anorexia nervosa and Acquired Immune Deficiency Syndrome
'Following on from the trial, IHL has now commenced preparation of a pre-Investigational New Drug (IND) meeting package “and is targeting a pre-IND meeting with the U.S. Food and Drug Administration (FDA) in Q1 2022”, Incannex said.
looking forward to that pre IND submission / outcome
2022 appears to be shaping up as 'the year' for Incannex
